Bertrand Tombal
贝特朗·汤巴尔
MD, PhD
Professor and Chairman, Division of Urology泌尿外科学部教授兼主任
👥Biography 个人简介
Prof. Bertrand Tombal is a leading Belgian urologic oncologist at Cliniques Universitaires Saint-Luc specializing in androgen deprivation therapy and non-metastatic CRPC. He has led key trials of GnRH antagonists and contributed to the SPARTAN trial establishing apalutamide for nmCRPC, shaping guidelines for ADT-based treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Non-Metastatic CRPC and Apalutamide
Contributed to the SPARTAN phase III trial demonstrating apalutamide plus ADT significantly improved metastasis-free survival in high-risk nmCRPC, leading to FDA approval and changing management of this disease state.
GnRH Antagonist Therapy in Prostate Cancer
Conducted pivotal comparative trials of GnRH antagonists versus GnRH agonists in ADT for advanced prostate cancer, demonstrating improved cardiovascular safety and testosterone suppression with antagonist approach.
Representative Works 代表性著作
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer (SPARTAN)
New England Journal of Medicine (2018)
Phase III trial demonstrating apalutamide extended metastasis-free survival by over 2 years in high-risk nmCRPC.
Degarelix as an Androgen Deprivation Therapy in Prostate Cancer: Cardiovascular and Metabolic Effects
European Urology (2014)
Comparative study showing GnRH antagonist degarelix reduces cardiovascular events versus LHRH agonist in men with pre-existing heart disease.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 贝特朗·汤巴尔 的研究动态
Follow Bertrand Tombal's research updates
留下邮箱，当我们发布与 Bertrand Tombal（Cliniques Universitaires Saint-Luc）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment